Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:CRSP NASDAQ:MRUS NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$12.54+1.0%$11.89$3.72▼$13.50$1.43B0.351.93 million shs1.14 million shsCRSPCRISPR Therapeutics$61.19+5.8%$56.86$30.04▼$71.13$5.57B1.812.55 million shs4.61 million shsMRUSMerus$66.90-1.7%$64.40$33.19▼$70.65$5.06B1.19846,637 shs634,696 shsRNAAvidity Biosciences$41.44+3.0%$41.12$21.51▼$56.00$5.33B0.992.06 million shs3.38 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-1.97%-2.13%+4.37%+62.86%+16.75%CRSPCRISPR Therapeutics+2.81%+6.91%-3.16%+33.92%+18.19%MRUSMerus-2.14%+1.34%+1.25%+28.28%+35.80%RNAAvidity Biosciences-10.10%-16.30%-13.45%+36.99%-3.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$12.54+1.0%$11.89$3.72▼$13.50$1.43B0.351.93 million shs1.14 million shsCRSPCRISPR Therapeutics$61.19+5.8%$56.86$30.04▼$71.13$5.57B1.812.55 million shs4.61 million shsMRUSMerus$66.90-1.7%$64.40$33.19▼$70.65$5.06B1.19846,637 shs634,696 shsRNAAvidity Biosciences$41.44+3.0%$41.12$21.51▼$56.00$5.33B0.992.06 million shs3.38 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-1.97%-2.13%+4.37%+62.86%+16.75%CRSPCRISPR Therapeutics+2.81%+6.91%-3.16%+33.92%+18.19%MRUSMerus-2.14%+1.34%+1.25%+28.28%+35.80%RNAAvidity Biosciences-10.10%-16.30%-13.45%+36.99%-3.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.92Moderate Buy$20.0059.49% UpsideCRSPCRISPR Therapeutics 2.47Hold$71.6017.01% UpsideMRUSMerus 3.08Buy$88.7532.66% UpsideRNAAvidity Biosciences 3.06Buy$68.9466.37% UpsideCurrent Analyst Ratings BreakdownLatest COGT, RNA, MRUS, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $65.009/12/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$68.00 ➝ $87.009/10/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $65.009/10/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/2/2025COGTCogent BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$30.008/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.008/25/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.008/8/2025RNAAvidity BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$70.00 ➝ $75.008/8/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$59.00 ➝ $62.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ACRSPCRISPR Therapeutics$37.31M149.16N/AN/A$22.64 per share2.70MRUSMerus$36.13M140.04N/AN/A$9.46 per share7.07RNAAvidity Biosciences$10.90M489.11N/AN/A$11.94 per share3.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)Latest COGT, RNA, MRUS, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A4.194.19CRSPCRISPR TherapeuticsN/A16.6116.61MRUSMerusN/A8.398.39RNAAvidity BiosciencesN/A9.269.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ACRSPCRISPR Therapeutics69.20%MRUSMerus96.14%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences7.29%CRSPCRISPR Therapeutics4.10%MRUSMerus3.70%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.22 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableCOGT, RNA, MRUS, and CRSP HeadlinesRecent News About These CompaniesAvidity Biosciences (NASDAQ:RNA) Trading Down 5.3% - Here's What Happened1 hour ago | marketbeat.comBank of America Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock Price2 hours ago | marketbeat.comAvidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 15 at 4:01 PM | prnewswire.comRhumbline Advisers Has $4.86 Million Stock Position in Avidity Biosciences, Inc. $RNASeptember 15 at 3:45 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Up on Analyst UpgradeSeptember 14 at 10:14 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Given New $87.00 Price Target at HC WainwrightSeptember 14 at 8:26 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives $67.00 Average Target Price from AnalystsSeptember 14 at 4:45 AM | americanbankingnews.comAvidity Biosciences (RNA) Gets 9% Boost from Higher PT, RatingSeptember 13 at 4:33 PM | msn.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - What's Next?September 13 at 12:16 PM | marketbeat.comAvidity Biosciences reports data from DMD treatment trialsSeptember 12, 2025 | msn.comAvidity Biosciences (NASDAQ:RNA) Given New $65.00 Price Target at Needham & Company LLCSeptember 12, 2025 | marketbeat.comAvidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Chardan CapitalSeptember 12, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Director Troy Edward Wilson Sells 29,500 SharesSeptember 11, 2025 | marketbeat.comAvidity Biosciences Announces Pricing of Upsized Public Offering of Common StockSeptember 11, 2025 | prnewswire.comAvidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-ZotaSeptember 11, 2025 | seekingalpha.comWhy Is Avidity Biosciences Stock Down 20% Pre-market Today?September 11, 2025 | msn.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from AnalystsSeptember 11, 2025 | marketbeat.comAvidity Shares Climb on Promising DMD44 Trial Results for Del-zotaSeptember 11, 2025 | msn.comAvidity Biosciences (NASDAQ:RNA) Price Target Raised to $65.00 at Needham & Company LLCSeptember 11, 2025 | americanbankingnews.comAvidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)September 10, 2025 | seekingalpha.comCantor finds Avidity data highly supportive of del-zota best-in-class potentialSeptember 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesChevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 20252 Powerful Forces Now Back Intel's TurnaroundBy Jeffrey Neal Johnson | August 20, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a TrendBy Jeffrey Neal Johnson | August 26, 2025COGT, RNA, MRUS, and CRSP Company DescriptionsCogent Biosciences NASDAQ:COGT$12.54 +0.13 (+1.05%) Closing price 04:00 PM EasternExtended Trading$12.89 +0.35 (+2.78%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$61.19 +3.35 (+5.79%) Closing price 04:00 PM EasternExtended Trading$61.01 -0.18 (-0.30%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Merus NASDAQ:MRUS$66.90 -1.19 (-1.75%) Closing price 04:00 PM EasternExtended Trading$66.88 -0.03 (-0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Avidity Biosciences NASDAQ:RNA$41.44 +1.22 (+3.03%) Closing price 04:00 PM EasternExtended Trading$42.75 +1.31 (+3.16%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
